Novartis Targets Breast Cancer With Novel PI3Kα Inhibitor Deal
Novartis has announced a strategic agreement with Synnovation Therapeutics, LLC to acquire SNV4818, an investigational oral therapy designed to treat hormone receptor-positive,…
Read More...
Read More...
